Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary Remove Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter Summaries of opinion (13) Apply Summaries of opinion filter Withdrawn applications (37) Apply Withdrawn applications filter Paediatric investigation plans (68) Apply Paediatric investigation plans filter Orphan designations (46) Apply Orphan designations filter Direct healthcare professional communication (17) Apply Direct healthcare professional communication filter

Product number

Authorisation status

Authorised (418) Apply Authorised filter Refused (3) Apply Refused filter Withdrawn (95) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Referral name

Referral status

European Commission final decision (9) Apply European Commission final decision filter Procedure started (1) Apply Procedure started filter

Referral safety status

Yes (3) Apply Yes filter

Referral type

Article 20 procedures (6) Apply Article 20 procedures filter Article 31 referrals (3) Apply Article 31 referrals filter Article 82 (1) Apply Article 82 filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (5) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (6) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (4) Apply Risk minimisation measures filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Decision date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter Conditional approval Remove Conditional approval filter Generic Remove Generic filter Additional monitoring (396) Apply Additional monitoring filter Exceptional circumstances (49) Apply Exceptional circumstances filter Orphan medicine (161) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

526 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter

Medicine type Conditional approval Remove Conditional approval filter Generic Remove Generic filter Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter

Categories Human Remove Human filter Veterinary Remove Veterinary filter

Sort by

List item

Human medicine European public assessment report (EPAR): Abasaglar (previously Abasria)

insulin glargine, Diabetes Mellitus
Date of authorisation: 09/09/2014, , Revision: 12, Authorised, Last updated: 24/09/2021
List item

Human medicine European public assessment report (EPAR): Abecma

idecabtagene vicleucel, Multiple Myeloma; Neoplasms; Cancer; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Infectious Mononucleosis; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases
Date of authorisation: 18/08/2021, , , , Revision: 6, Authorised, Last updated: 27/07/2023
List item

Human medicine European public assessment report (EPAR): Abevmy

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 21/04/2021, , , Revision: 5, Authorised, Last updated: 15/12/2022
List item

Human medicine European public assessment report (EPAR): Abiraterone Accord

abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 26/04/2021, , Revision: 1, Authorised, Last updated: 25/09/2023
List item

Human medicine European public assessment report (EPAR): Abiraterone Krka

abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 24/06/2021, , Revision: 2, Authorised, Last updated: 08/03/2023
List item

Human medicine European public assessment report (EPAR): Abiraterone Mylan

abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 20/08/2021, , Revision: 4, Authorised, Last updated: 11/09/2023
List item

Human medicine European public assessment report (EPAR): Abrysvo

Respiratory syncytial virus, subgroup A, stabilized prefusion F protein / Respiratory syncytial virus, subgroup B, stabilized prefusion F protein, Respiratory Syncytial Virus Infections
Date of authorisation: 23/08/2023, , , Authorised, Last updated: 26/09/2023
List item

Human medicine European public assessment report (EPAR): Abseamed

epoetin alfa, Anemia; Kidney Failure, Chronic; Cancer
Date of authorisation: 27/08/2007,
Date of refusal: 18/06/2009, , Revision: 22, Authorised, Last updated: 21/08/2023
List item

Human medicine European public assessment report (EPAR): Accofil

filgrastim, Neutropenia
Date of authorisation: 17/09/2014, , Revision: 14, Authorised, Last updated: 24/07/2023
List item

Human medicine European public assessment report (EPAR): Actelsar HCT

Telmisartan, hydrochlorothiazide, Essential Hypertension
Date of authorisation: 13/03/2013, , Revision: 17, Authorised, Last updated: 24/10/2023
List item

Veterinary medicine European public assessment report (EPAR): Acticam

meloxicam, Dogs; Cats
Date of authorisation: 09/12/2008, , Revision: 9, Withdrawn, Last updated: 24/03/2021
List item

Human medicine European public assessment report (EPAR): Adakveo

Crizanlizumab, Anemia, Sickle Cell
Date of authorisation: 28/10/2020, , , Revision: 6, Withdrawn, Last updated: 29/09/2023
List item

Human medicine European public assessment report (EPAR): Alpheon

recombinant human interferon alfa-2a, Hepatitis C, Chronic
Date of refusal: 05/09/2006, , Refused, Last updated: 28/06/2006
List item

Human medicine European public assessment report (EPAR): Alymsys

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021, , , Revision: 6, Authorised, Last updated: 26/07/2023
List item

Human medicine European public assessment report (EPAR): Ambrisentan Mylan

ambrisentan, Hypertension, Pulmonary
Date of authorisation: 20/06/2019, , Revision: 4, Authorised, Last updated: 26/04/2023
List item

Human medicine European public assessment report (EPAR): Amgevita

adalimumab, Arthritis, Psoriatic; Colitis, Ulcerative; Arthritis, Juvenile Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Crohn Disease; Arthritis, Rheumatoid
Date of authorisation: 21/03/2017, , Revision: 11, Authorised, Last updated: 18/01/2023
List item

Human medicine European public assessment report (EPAR): Amifampridine SERB

amifampridine phosphate, Lambert-Eaton Myasthenic Syndrome; Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Paraneoplastic Syndromes; Nervous System Diseases; Autoimmune Diseases of the Nervous System; Neurodegenerative Diseases; Neuromuscular Diseases; Neuromuscular Junction Diseases; Immune System Diseases; Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Cancer; Neoplasms
Date of authorisation: 19/05/2022, , Authorised, Last updated: 24/05/2022
List item

Human medicine European public assessment report (EPAR): Amlodipine / Valsartan Mylan

Amlodipine besilate, valsartan, Hypertension
Date of authorisation: 22/03/2016, , Revision: 11, Authorised, Last updated: 17/08/2023
List item

Human medicine European public assessment report (EPAR): Amsparity

adalimumab, Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthritis, Juvenile Rheumatoid
Date of authorisation: 13/02/2020, , , Revision: 4, Authorised, Last updated: 29/10/2021
List item

Human medicine European public assessment report (EPAR): Amversio

betaine, Homocystinuria
Date of authorisation: 05/05/2022, , Authorised, Last updated: 08/06/2023
List item

Human medicine European public assessment report (EPAR): Anagrelide Mylan

Anagrelide hydrochloride, Thrombocythemia, Essential
Date of authorisation: 15/02/2018, , Revision: 8, Authorised, Last updated: 11/05/2023
List item

Human medicine European public assessment report (EPAR): Apixaban Accord

Apixaban, Venous Thromboembolism; Stroke; Arthroplasty
Date of authorisation: 23/07/2020, , Revision: 2, Authorised, Last updated: 19/05/2022
List item

Human medicine European public assessment report (EPAR): Arepanrix

split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs., Influenza, Human; Immunization; Disease Outbreaks
Date of authorisation: 23/03/2010, , Revision: 1, Withdrawn, Last updated: 25/10/2011
List item

Human medicine European public assessment report (EPAR): Aripiprazole Accord

aripiprazole, Schizophrenia; Bipolar Disorder
Date of authorisation: 15/11/2015, , Revision: 15, Authorised, Last updated: 13/07/2022
List item

Human medicine European public assessment report (EPAR): Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)

aripiprazole, Schizophrenia; Bipolar Disorder
Date of authorisation: 30/06/2015, , Revision: 16, Authorised, Last updated: 08/09/2023